DEFINIZIONE ED ASPETTI SISTEMICI
G. Bettoncelli, L.M. Fabbri
1) Laghi F, Langbein WE, Antonescu-Turcu A, Jubran A, Bammert C, Tobin MJ.
Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2005;171:598-605
2) Laghi F, Antonescu-Turcu A, Collins E, Segal J, Tobin DE, Jubran A, Tobin MJ.
Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life.
Am J Respir Crit Care Med 2005;171:728-733
3) Fishman AP. One Hundred Years of COPD.
Am J Respir Crit Care Med 2005;
171:941-948
4) Takabatake N, Sata M, Inoue S, Shibata Y, Abe S, Wada T, Machiya J, Ji G,
Matsuura T, Takeishi Y, Muramatsu M, Kubota I. A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med
2005;172:1097-1104
5) Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M,
Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2005;172:189-194
6) Saey D, Michaud A, Couillard A, Cote CH, Mador MJ, LeBlanc P, Jobin J, Maltais F.
Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2005;171:1109-1115
7) Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, Bouillon R,
Decramer M. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med
2005;172:1105-1111
8) Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.
Jama 2005;294:716-724
9) Koechlin C, Maltais F, Saey D, Michaud A, LeBlanc P, Hayot M, Prefaut C.
Hypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease.
Thorax 2005;60:834-841
10) Agusti AG. Systemic effects of chronic obstructive pulmonary disease.
Proc
Am Thorac Soc 2005;2:367-70; discussion 371-372
11) Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care.
Chest
2005; 128 (4): 2099-2107

12) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005.
A collaborative project of the National Health L, and Blood Institute, NIH and the
World Health Organisation., ed. www.goldcopd.com: National Institutes of Health,
National Heart Lund and Blood Institute, Bethesda, Md, 2005.
13) Shapiro SD. COPD Unwound.
N Engl J Med 2005; 352(19): 2016-2019
14) Mannino D. Chronic obstructive pulmonary disease in 2025: where are we headed.
Eur Respir J 2005; 26: 189
15) Sin DD. and Man SF.
Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Morbidity and Mortality . Proc Am Thorac Soc Vol 2. pp 8
–11,
2005
16) Donald B. Hunninghake.
Cardiovascular Disease in Chronic Obstructive
Pulmonary Disease.
Proc Am Thorac Soc Vol 2. pp 44 –49, 2005
17) Semenza GL. Pulmonary Vascular Responses to Chronic Hypoxia Mediated by Hypoxia-inducible Factor 1.
Proc Am Thorac Soc Vol 2. pp 68
–70, 2005
18) Agustı AG, Noguera A., Sauleda J., Sala E., Pons J., Busquets X. Systemic effects of chronic obstructive pulmonary disease . Eur Respir J 2003; 21: 347
–
360
19) Gan WQ, Man SF, Senthilselvan A and Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574 –580.
20) Wouters EF. Introduction: systemic effects in chronic obstructive pulmonary disease.
Eur Respir J 2003; 22: Suppl. 46, 1s.
21) Higenbottam T. Pulmonary Hypertension and Chronic Obstructive Pulmonary
Disease . Proc Am Thorac Soc Vol 2. pp 12 –19, 2005
22) Wouters EF. Local and Systemic Inflammation in Chronic Obstructive
Pulmonary Disease.
Proc Am Thorac Soc Vol 2. pp 26 –33, 2005
23) MacNee W. Pulmonary and Systemic Oxidant/Antioxidant Imbalance in
Chronic Obstructive Pulmonary Disease.
Proc Am Thorac Soc Vol 2. pp 50
–60,
2005
24) Tapson VF. The Role of Smoking in Coagulation and Thromboembolism in
Chronic Obstructive Pulmonary Disease.
Proc Am Thorac Soc Vol 2. pp 71 –77,
2005
25) Rennard SI.
Clinical Approach to Patients with Chronic Obstructive
Pulmonary Disease and Cardiovascular Disease. Proc Am Thorac Soc Vol 2. pp
94 –100, 2005

26) Mannino DM., Doherty DE., Buist AS. Global Initiative on Obstructive Lung
Disease (GOLD) classification of lung disease and mortality: findings from the
Atherosclerosis Risk in Communities (ARIC) study.
In press
27) Sin DD. and Man SF.
Can inhaled steroids mend a broken heart in chronic obstructive pulmonary disease?
Eur Respir J 2005; 25: 589 –590
28) Naeije R. Pulmonary Hypertension and Right Heart Failure in Chronic
Obstructive Pulmonary Disease.
Proc Am Thorac Soc Vol 2. pp 20 –22, 2005
29) MacCallum PK. Markers of Hemostasis and Systemic Inflammation in Heart
Disease and Atherosclerosis in Smokers.
Proc Am Thorac Soc Vol 2. pp 34
–43,
2005
30) van Eeden SF., Yeung A, Quinlam K, and Hogg JC. Systemic Response to
Ambient Particulate Matter Relevance to Chronic Obstructive Pulmonary
Disease.
Proc Am Thorac Soc Vol 2. pp 61 –67, 2005
31) Man SF and Sin DD.. Effects of Corticosteroids on Systemic Inflammation in
Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 78 –82,
2005
32) Celli BR., Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto
Plata V, and Cabral HJ. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease.
N
Engl J Med 2004;350:1005-12.
33) Sunyer J. and Ulrik CS.
Level of FEV1 as a predictor of all-cause and cardiovascular mortality: an effect beyond smoking and physical fitness?
Eur
Respir J 2005; 25: 587 –588
34) Huiart L, Ernst P, Ranouil X and Suissa S.
Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD.
Eur Respir J 2005; 25:
634 –639
35) Stavem K, Aaser E, Sandvik L , Bjørnholt JV, Erikssen G, Thaulow E and Erikssen
J. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males.
Eur Respir J 2005; 25: 618
–625